Supernus Reports Record 2025 Revenues, GAAP Loss Due to Acquisition Costs, and Provides 2026 Guidance
SUPN sits 90% above its 52-week low of $29.16 on elevated volume (3.1× avg).
Summary
Supernus Pharmaceuticals announced record 2025 revenues, but reported a GAAP operating and net loss due to acquisition costs, while providing 2026 guidance projecting a return to GAAP operating earnings.
Key Events · Earnings and Guidance · SUPN
-
Record 2025 Revenues Reported
Supernus achieved record total revenues of $211.6 million in Q4 2025 (up 21% YoY) and $719.0 million for the full year 2025 (up 9% YoY), driven by strong performance in growth products.
-
Shift to GAAP Operating and Net Loss
The company reported a GAAP operating loss of $(62.3) million and a net loss of $(38.6) million for the full year 2025, a significant decrease from 2024's GAAP profitability, primarily due to acquisition-related costs from the Sage acquisition.
-
Strong Growth in Key Products
Combined revenues from Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO increased 40% year-over-year to $521.8 million for the full year 2025.
-
Provides Full Year 2026 Guidance
Supernus expects full year 2026 total revenues between $840 million and $870 million, with GAAP operating earnings projected to be $0 million to $30 million, indicating a return to profitability.
Analysis · SUPN · Life Sciences
Supernus Pharmaceuticals reported record total revenues for both the fourth quarter and full year 2025, driven by strong growth in its four key products, including the newly acquired ZURZUVAE and ONAPGO. However, the company posted a GAAP operating loss and net loss for 2025, a significant decline from 2024's profitability. This shift was primarily attributed to substantial acquisition-related costs associated with the Sage acquisition and increased intangible asset amortization. Despite the GAAP losses, non-GAAP adjusted operating earnings remained robust, indicating underlying business strength. The company also provided full-year 2026 guidance, projecting a return to GAAP operating earnings, albeit lower than 2024 levels, and continued growth in total revenues. The resumption of new patient initiation for ONAPGO is a positive operational development. The market's focus will likely be on the continued performance of growth products and the realization of synergies from the Sage acquisition as the company navigates its path back to consistent GAAP profitability.
At the time of this filing, SUPN was trading at $55.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $29.16 to $57.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.